Reduced sensitivity of SARS-CoV-2 variant Delta to antibody neutralization

Nature, Journal Year: 2021, Volume and Issue: 596(7871), P. 276 - 280

Published: July 8, 2021

Language: Английский

---

The biological and clinical significance of emerging SARS-CoV-2 variants

Nature Reviews Genetics, Journal Year: 2021, Volume and Issue: 22(12), P. 757 - 773

Published: Sept. 17, 2021

Language: Английский

---

Comparing COVID-19 vaccines for their characteristics, efficacy and effectiveness against SARS-CoV-2 and variants of concern: a narrative review

Clinical Microbiology and Infection, Journal Year: 2021, Volume and Issue: 28(2), P. 202 - 221

Published: Oct. 27, 2021

Language: Английский

---

SARS-CoV-2 Spike Mutations, L452R, T478K, E484Q and P681R, in the Second Wave of COVID-19 in Maharashtra, India

Microorganisms, Journal Year: 2021, Volume and Issue: 9(7), P. 1542 - 1542

Published: July 20, 2021

As the global severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) pandemic expands, genomic epidemiology and whole genome sequencing are being used to investigate its transmission evolution. Against backdrop of emergence "variants concern" (VOCs) during December 2020 an upsurge in a state western part India since January 2021, analysis spike protein mutations using sequence structural approaches were undertaken identify possible new variants gauge fitness current circulating strains. Phylogenetic revealed that newly identified lineages B.1.617.1 B.1.617.2 predominantly circulating. The signature possessed by these strains L452R, T478K, E484Q, D614G P681R protein, including within receptor-binding domain (RBD). Of these, at residue positions 452, 484 681 have been reported other globally lineages. RBD T478K E484Q may possibly result increased ACE2 binding while furin cleavage site could increase rate S1-S2 cleavage, resulting better transmissibility. two mutations, L452R indicated decreased select monoclonal antibodies (mAbs) affect their neutralization potential. Further vitro/in vivo studies would help confirm phenotypic changes mutant Overall, study emerged responsible for second wave COVID-19 Maharashtra. Lineage has designated as VOC delta variant interest kappa, they widely rest country well globally. Continuous monitoring emerging is essential.

Language: Английский

---

Tackling COVID-19 with neutralizing monoclonal antibodies

Cell, Journal Year: 2021, Volume and Issue: 184(12), P. 3086 - 3108

Published: May 26, 2021

Language: Английский

---

Casirivimab and imdevimab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial

The Lancet, Journal Year: 2022, Volume and Issue: 399(10325), P. 665 - 676

Published: Feb. 1, 2022

Language: Английский

---

SARS-CoV-2 variant evasion of monoclonal antibodies based on in vitro studies

Nature Reviews Microbiology, Journal Year: 2022, Volume and Issue: 21(2), P. 112 - 124

Published: Oct. 28, 2022

Language: Английский

---

Impact of the Delta variant on vaccine efficacy and response strategies

Expert Review of Vaccines, Journal Year: 2021, Volume and Issue: 20(10), P. 1201 - 1209

Published: Sept. 7, 2021

The Delta variant of SARS-CoV-2 has caused a new wave the COVID-19 epidemic in many countries. It is most infectious to date, and its high infectivity means that higher proportion population needs be vaccinated reduce disease burden, which poses substantial public health challenge.The evolution reviewed, including an overview Plus with K417N mutation RBD, may confer improved immune evasion ability. Decreases serum neutralizing antibody titers after vaccination against were greater than those Alpha but less Beta. protective efficacy existing vaccines have declined related number doses time since vaccination.The currently used are effective hospitalization/severe due variant. Accelerating popularization vaccination, improving coverage rate, implementation intervention measures, such as wearing masks, control spread other variants. However, alone without measures lead continuous emergence

Language: Английский

---

Monoclonal antibody therapies against SARS-CoV-2

The Lancet Infectious Diseases, Journal Year: 2022, Volume and Issue: 22(11), P. e311 - e326

Published: July 5, 2022

Language: Английский

---

Monoclonal antibodies for COVID-19 therapy and SARS-CoV-2 detection

Journal of Biomedical Science, Journal Year: 2022, Volume and Issue: 29(1)

Published: Jan. 4, 2022

The coronavirus disease 2019 (COVID-19) pandemic is an exceptional public health crisis that demands the timely creation of new therapeutics and viral detection. Owing to their high specificity reliability, monoclonal antibodies (mAbs) have emerged as powerful tools treat detect numerous diseases. Hence, many researchers begun urgently develop Ab-based kits for detection severe acute respiratory syndrome 2 (SARS-CoV-2) Ab drugs use COVID-19 therapeutic agents. detailed structure SARS-CoV-2 spike protein known, since this key infection, its receptor-binding domain (RBD) has become a major target development. Because RNA virus with mutation rate, especially under selective pressure aggressively deployed prophylactic vaccines neutralizing Abs, cocktails expected be important strategy effective treatment. Moreover, infection may stimulate overactive immune response, resulting in cytokine storm drives progression. Abs combat storms also been intense development treatments COVID-19. In addition drugs, are currently being utilized tests, including antigen immunoglobulin tests. Such tests crucial surveillance can used prevent spread Herein, we highlight some points regarding mAb-based pandemic.

Language: Английский

---